INSERM (Institut National de la Santé et de la Recherche Médicale) Patent applications |
Patent application number | Title | Published |
20130316961 | TREATMENT OF MECP-2 ASSOCIATED DISORDERS - The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome. | 11-28-2013 |
20130225905 | DEVICE THAT IS IMPLANTABLE IN THE TEMPORAL BONE FOR DELIVERING A MATERIAL, AND HEARING AID PROVIDED WITH SUCH A DEVICE - A device that is implantable in the temporal bone for dispensing at least one component of a liquid product, comprising a catheter and means for moving the component along the catheter, wherein the product incorporates particles for transporting the component, the particles being movable under the effect of a magnetic field, wherein the catheter comprises portions for discharging the component from the catheter, the discharging portions being distributed along the catheter, and wherein the moving means comprise means for generating a magnetic field near each discharging portion so as to move the product from discharging portion to discharging portion, the field-generating means comprising windings that surround the discharging portions and that are connected to a control module designed to successively power at least some of the windings. | 08-29-2013 |
20080280318 | Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof - The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells. | 11-13-2008 |